Employees: 02 (2023.0)Legal category: 5785Size: PMECreation date: 2007-07-01 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LYON (69008), Rhone
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE AMBROISE PARE : revenue, balance sheet and financial ratios
PHARMACIE AMBROISE PARE is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LYON (69008),
this company of category PME
shows in 2024 a net income positive of 11 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE AMBROISE PARE (SIREN 499033116)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
10 770 €
17 894 €
44 089 €
-60 695 €
174 556 €
28 077 €
26 848 €
36 527 €
-23 668 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE AMBROISE PARE generates positive net income of 11 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
10 770 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 214%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 28%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
214.488%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
27.842%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE AMBROISE PARE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
1175.626
854.18
693.066
576.383
244.917
261.268
220.173
212.655
214.488
Financial autonomy
6.367
8.369
10.267
12.257
23.714
23.195
26.87
27.897
27.842
Repayment capacity
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
214.492024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average
In 2024, the debt ratio of PHARMACIE AMBROISE PARE (214.49) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
27.84%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Watch
In 2024, the financial autonomy of PHARMACIE AMBROISE PARE (27.8%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 163.50. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
163.502
Liquidity indicators evolution PHARMACIE AMBROISE PARE
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
74.382
84.69
83.308
79.662
71.458
105.799
116.471
137.381
163.502
Interest coverage
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
163.52024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average+21 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE AMBROISE PARE (163.50) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Positioning of PHARMACIE AMBROISE PARE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE AMBROISE PARE is estimated at
150 357 €
(range 104 706€ - 224 942€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
104k€150k€224k€
150 357 €Range: 104 706€ - 224 942€
NAF 5 année 2024
Valuation method used
Net Income Multiple
10 770 €
×
14.0x
=150 357 €
Range: 104 706€ - 224 943€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE AMBROISE PARE with other companies in the same sector:
Frequently asked questions about PHARMACIE AMBROISE PARE
What is the revenue of PHARMACIE AMBROISE PARE ?
The revenue of PHARMACIE AMBROISE PARE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE AMBROISE PARE profitable?
Yes, PHARMACIE AMBROISE PARE generated a net profit of 11 k€ in 2024.
Where is the headquarters of PHARMACIE AMBROISE PARE ?
The headquarters of PHARMACIE AMBROISE PARE is located in LYON (69008), in the department Rhone.
Where to find the tax return of PHARMACIE AMBROISE PARE ?
The tax return of PHARMACIE AMBROISE PARE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE AMBROISE PARE operate?
PHARMACIE AMBROISE PARE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart